Duramed has received FDA approval for LoSeasonique (levonorgestrel 0.10mg/ethinyl estradiol 0.02mg and ethinyl estradiol 0.01mg tablets), an extended-cycle oral contraceptive that reduces the number of withdrawal bleeding periods from 13 to 4 per year. This approval is supported by data from a 12-month, open-label clinical trial of over 2,100 women, demonstrating the effectiveness of LoSeasonique’s low-dose, extended-cycle regimen.

LoSeasonique is expected to be available in the first quarter of 2009.

For more information call (800) BARR LAB or visit www.barrlabs.com.